SCHEMBL6096515

SCHEMBL6096515

Cc1nc(Cl)c([N+](=O)[O-])c(CCCCNC(=O)OC(C)(C)C)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.41
STK17B O94768 1/20 0.40
STK17A Q9UEE5 1/20 0.40
POLB P06746 1/20 0.40
BRD4 O60885 2/20 0.40
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
GAA P10253 1/20 0.37
CA12 O43570 5/20 0.36
CA1 P00915 5/20 0.36
CA2 P00918 5/20 0.36
CA9 Q16790 5/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
DRD2 P14416 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490695 0.86 STK17B (0.44) TDP1STK17BSTK17APOLBBRD4
SCHEMBL6645960 0.85 POLB (0.46) POLBMEN1KMT2ALMNAHPGD
SCHEMBL6645966 0.85 POLB (0.46) POLBMEN1KMT2ALMNAHPGD
SCHEMBL6097448 0.84 STK17B (0.47) TDP1STK17BSTK17APOLBBRD4
SCHEMBL5030437 0.81 POLB (0.41) TDP1STK17BSTK17APOLBBRD4
SCHEMBL27538313 0.78 POLB (0.36) POLB
SCHEMBL5334549 0.78 POLB (0.39) TDP1STK17BSTK17APOLBBRD4
SCHEMBL6098426 0.77 BRD4 (0.47) TDP1STK17BSTK17ABRD4
SCHEMBL4300592 0.74 GAA (0.41) TDP1POLBMEN1KMT2AGAA
SCHEMBL12776916 0.73 POLB (0.38) STK17BSTK17APOLBBRD4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101220028-A Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES CO (US) 2008-07-16 CN disclosed
CN-100402528-C Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES CO (US) 2008-07-16 CN disclosed
CN-100387597-C Amido-substituted imidazopyridines 3M INNOVATIVE PROPERTIES CO (US) 2008-05-14 CN disclosed
CN-100372846-C Sulfonamido substituted imidazopyridines 3M INNOVATIVE PROPERTIES CO (US) 2008-03-05 CN disclosed
US-7098221-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-08-29 US disclosed
CN-1249062-C Substituted imidazopyridines 3M INNOVATIVE PROPERTIES CO (US) 2006-04-05 CN disclosed
US-20050282854-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2005-12-22 US disclosed
US-6969722-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-11-29 US disclosed
US-6903113-B2 Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-07 US disclosed
US-6878719-B2 Sulfonamido substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-04-12 US disclosed
EP-1343783-A2 SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2003-09-17 EP disclosed
US-20030162806-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 US disclosed
WO-2003050118-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
WO-2003050119-A2 UREA SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
WO-2003050117-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
US-6545017-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 US disclosed
US-6545016-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 US disclosed
US-6525064-B1 Immune response modifiers; can induce the biosynthesis of various cytokines; 3M INNOVATIVE PROPERTIES COMPANY 2003-02-25 US disclosed
US-20020107262-A1 SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2002-08-08 US disclosed
WO-2002046194-A2 SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282854-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG TDP1 3359/4885STK17B 3251/4885STK17A 2848/4885
US-20020107262-A1 SUBSTITUTED IMIDAZOPYRIDINES IRF3, IFNG, EIF2AK2 TDP1 2709/4885STK17B 2873/4885STK17A 2644/4885
US-20030162806-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG TDP1 3359/4885STK17B 3251/4885STK17A 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.